Highlight Therapeutics
PrivateLast Round
VC Round
Sep 16, 2025
Total Funding Raised
$27.12M
Company Overview
Highlight Therapeutics is a Spanish clinical-stage biopharmaceutical company that develops RNA-based immuno-oncology therapies. The company's primary focus is on its lead drug candidate, BO-112, an intra-lesional RNA-based therapy designed to initiate a powerful immune response. This therapy works by mimicking a viral infection, which turns immunologically inactive 'cold' tumors into 'hot' ones, making them visible and susceptible to the body's immune system. BO-112 has the potential to help patients who are resistant to checkpoint inhibitor therapies and is being investigated in multiple clinical trials, both as a monotherapy and in combination with other treatments for various cancers, including melanoma, liver metastases, and basal cell carcinoma. The company, formerly known as Bioncotech Therapeutics, rebranded in April 2020. It is privately held and backed by venture capital, having recently closed a €15 million funding round in September 2025 to advance its clinical trials.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Highlight Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Highlight Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 16, 2025 | ||||
| Series B | Feb 4, 2021 |
Key People
Founding team and executive leadership
Highlight Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Advent Life Sciences | Series B |
| GED Capital | VC Round |
| Buenavista Equity Partners | VC Round |
| Columbus Venture Partners | VC Round, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 16, 2025
$18M raised in a VC Round.
- Sep 4, 2025
Abel Riera appointed as new Chief Business Officer.
Highlight Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Highlight Therapeutics's valuation, stock price, and market status.
